TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-08-16 am EDT
3801.00 JPY    0.00%
08/04TAKEDA PHARMACEUTICAL : Quarterly Securities Report for the 1st Quarter
PU
08/03Poseida Therapeutics Shares Soar After Roche Collaboration
DJ
08/01Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda clears key hurdle as investors back $59 billion Shire deal

12/05/2018 | 10:37am EDT
FILE PHOTO: The logo of Takeda Pharmaceutical Co. is displayed at the company's news conference venue in Tokyo

OSAKA (Reuters) - Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire, creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt.

Takeda will be joining the ranks of the world's top 10 drugmakers and gaining expertise in rare diseases through the deal, the biggest overseas acquisition by a Japanese company.

It will also become one of the most indebted. In addition to issuing new shares, the company has secured $30.9 billion in bank loans.

The company's high debt levels were a top concern for Takeda shareholders who gathered at an extraordinary meeting in Osaka, western Japan, although almost 90 percent of them voted to approve the deal as expected.

"I want to keep my Takeda shares into the future, but now I am worried about further declines in the share price," said Satoshi Ito, a 75-year-old shareholder. He abstained from voting.

Separate meetings of Shire shareholders later on Wednesday also secured overwhelming support for the transaction.

Takeda shares have fallen around 25 percent since the drugmaker revealed its interest in the acquisition in March. They closed up 1 percent at 4,240 yen on Wednesday.

Shire shares gained 3.2 percent to 46.95 pounds on relief Takeda's board had won its nine-month battle to persuade shareholders of the merits of the tie-up.

The acquisition is expected to close on Jan. 8. It now only requires sanctioning at a court hearing expected to be held on Jan. 3.

DEBTS, DESCENDANTS AND DIVESTITURES

A small group of Takeda investors, including descendants of the company's founder, had actively opposed the deal.

"We are definitely against this because the financial risks are too great and the expected benefits are quite limited," said Kazuhisa Takeda, a former director of the drugmaker and a member of the founding family, ahead of the meeting.

"I think M&A is quite necessary for Takeda's future but Shire is not the answer."

Chief Executive Christophe Weber has promised to turn the deal profitable by slashing costs. It predicts annual savings of at least $1.4 billion three years after completion, and expects to boost underlying earnings significantly from the first full year after closing.

Takeda also has a plan to sell up to $10 billion worth of non-core assets to pay back debt. Andy Plump, Takeda's global head of R&D, told Reuters that accelerated deleveraging was needed to keep its credit rating at a safe level.

"We have a plan for divestiture that gets us to a place in three to five years that our credit agencies are OK with. Our credit rating is likely to tick down a notch, but still above junk bond status, which is critical for us," he said in an interview.

Analysts have said it may be difficult to integrate the two companies. Toshiba's acquisition of Westinghouse over a decade ago and Japan Post Holdings' $4.9 billion bet on Toll Holdings are widely seen as examples of many Japanese companies having paid high valuations in cross-border deals only to face massive write-downs later.

But they also said Takeda has little choice but to seek growth abroad, with industry pressure to gain access to cutting-edge treatments amid declining revenue from older drugs that must compete with cheaper generics.

Even with the acquisition of Shire, some said Takeda will need to bolster its lineup of experimental therapies to compete in the longer term.

Shire's haemophilia business, for example, is already starting to face strong pressure from a competing drug being marketed by Roche as well as new gene therapies now in development.

"It's crucial whether the drugmaker can reinvest profits from the deal into seeds for developing future drugs," said Kazuaki Hashiguchi, a senior drugs analyst at Daiwa Securities.

"The benefits of the deal will last for a limited time, as no treatments can avoid patent expiration."

(Reporting by Takashi Umekawa, with additional reporting by Julie Steenhuysen in Chicago and Ben Hirschler in London; Editing by Muralikumar Anantharaman/Mark Potter/Susan Fenton)

By Takashi Umekawa


© Reuters 2018
Stocks mentioned in the article
ChangeLast1st jan.
JAPAN POST HOLDINGS CO., LTD. 0.07% 957.7 Delayed Quote.6.71%
ROCHE HOLDING AG -0.71% 315.65 Delayed Quote.-16.14%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 0.00% 3801 Delayed Quote.21.17%
TOSHIBA CORPORATION -0.06% 5187 Delayed Quote.9.73%
US DOLLAR / JAPANESE YEN (USD/JPY) 0.80% 134.203 Delayed Quote.15.85%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
08/04TAKEDA PHARMACEUTICAL : Quarterly Securities Report for the 1st Quarter
PU
08/03Poseida Therapeutics Shares Soar After Roche Collaboration
DJ
08/01Jefferies Downgrades Takeda Pharmaceutical to Hold From Buy
MT
07/29Takeda Pharmaceutical's Fiscal Q1 Attributable Profit Slides 24%
MT
07/28TRANSCRIPT : Takeda Pharmaceutical Company Limited, Q1 2023 Earnings Call, Jul 28, 2022
CI
07/28Takeda Posts Higher Fiscal Q1 Core Profit, Revenue
MT
07/28Takeda Pharmaceutical's First-Quarter Net Profit Fell 24% From High Base
DJ
07/28Takeda sees quarterly profit drop 39% after last year's one-time gains
RE
07/28Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Managem..
BU
07/28Takeda Pharmaceutical Company Limited Announces Dividend Guidance for Second Quarter an..
CI
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2023 3 764 B 28 283 M 28 283 M
Net income 2023 307 B 2 306 M 2 306 M
Net Debt 2023 3 038 B 22 830 M 22 830 M
P/E ratio 2023 19,2x
Yield 2023 4,74%
Capitalization 5 877 B 44 162 M 44 162 M
EV / Sales 2023 2,37x
EV / Sales 2024 2,29x
Nbr of Employees 47 347
Free-Float 96,8%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 801,00 JPY
Average target price 4 561,33 JPY
Spread / Average Target 20,0%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED21.17%44 162
JOHNSON & JOHNSON-2.91%434 603
ELI LILLY AND COMPANY13.66%292 730
PFIZER, INC.-15.75%281 235
ROCHE HOLDING AG-16.91%275 562
ABBVIE INC.5.09%252 131